Presentation is loading. Please wait.

Presentation is loading. Please wait.

Overall and recurrence-free survival.

Published byOskar Klimek Modified over 5 years ago

Similar presentations

Presentation on theme: "Overall and recurrence-free survival."— Presentation transcript:

1 Overall and recurrence-free survival.
Overall and recurrence-free survival. (A) Kaplan-Meier curve comparing mortality of the lupus diffuse alveolar haemorrhage (DAH) group and the lupus controls. Lupus diagnosis is the point of reference and is set as time zero. (B) Kaplan-Meier curve demonstrating DAH recurrence-free survival in the lupus DAH group. Notably, all but one recurrence was within 6 months of the original episode. Nayef M Kazzaz et al. Lupus Sci Med 2015;2:e000117 ©2015 by Lupus Foundation of America

Download ppt "Overall and recurrence-free survival."

Similar presentations

Montalescot G, et al. Lancet 2009;373:723-31. Trial profile Montalescot G, et al. Lancet 2009;373:723-31.

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:
Fig. 3. Kaplan-Meier analyses of biochemical recurrence (BCR)-free survival rates according to ADCmeanvalues among the total subjects (A) and among the.

Fig. 3. Kaplan-Meier analyses of biochemical recurrence (BCR)-free survival rates according to ADCmeanvalues among the total subjects (A) and among the.
Oncol Res Treat 2016;39: DOI: /

Oncol Res Treat 2016;39: DOI: /
 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
Amir Jadidi et al. JACEP 2018;4:

Amir Jadidi et al. JACEP 2018;4:
Giuseppe Boriani et al. JACEP 2016;2:

Giuseppe Boriani et al. JACEP 2016;2:
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.
Mintu P. Turakhia et al. JACEP 2016;2:

Mintu P. Turakhia et al. JACEP 2016;2:
Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.

Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.
Kaplan-Meier curves for overall survival (OS) probability.

Kaplan-Meier curves for overall survival (OS) probability.
• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.
Enrollment and Outcomes

Enrollment and Outcomes
Impact of immunosuppressive therapy on pulmonary function, recurrence of diffuse alveolar haemorrhage (DAH) and chest computed tomography (CT) findings.

Impact of immunosuppressive therapy on pulmonary function, recurrence of diffuse alveolar haemorrhage (DAH) and chest computed tomography (CT) findings.
Overall survival by SCT versus observation in first complete remission

Overall survival by SCT versus observation in first complete remission
Kaplan-Meier survival curve demonstrating treatment duration of metformin and orlistat. Kaplan-Meier survival curve demonstrating treatment duration of.

Kaplan-Meier survival curve demonstrating treatment duration of metformin and orlistat. Kaplan-Meier survival curve demonstrating treatment duration of.
(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.
Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

Similar presentations

Ads by Google